|
| Press Releases |
|
 |
|
| Friday, September 1, 2017 |
|
|
Eisai to Present Abstracts on Oncology Products and Pipeline at ESMO 2017 Congress Three Abstracts on Lenvima (Lenvatinib) to be Presented in Oral Session |
| Eisai Co., Ltd. announced today that a series of abstracts will be presented during the European Society for Medical Oncology (ESMO) 2017 Congress , taking place in Madrid, Spain, from September 8 to 12, 2017. more info >> |
|
| Thursday, July 27, 2017 |
|
|
U.S. FDA Approves Additional Use of Antiepileptic Drug Fycompa as Monotherapy for Partial-Onset Seizures |
| Eisai Co., Ltd. has announced that its U.S. subsidiary Eisai Inc. received approval from the U.S. FDA for a supplemental New Drug Application (sNDA) for Eisai's antiepileptic drug (AED) Fycompa (perampanel) as monotherapy use for the treatment of partial-onset seizures (with or without secondarily generalized seizures) in patients with epilepsy 12 years of age and older. more info >> |
|
| Wednesday, July 26, 2017 |
|
|
Eisai Submits Simultaneous Applications in The United States and Europe for Lenvatinib in Hepatocellular Carcinoma |
| Eisai Co., Ltd. announced that it has submitted applications to the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA) for its in-house discovered and developed anticancer agent lenvatinib mesylate (lenvatinib) for the treatment of hepatocellular carcinoma (HCC). more info >> |
|
| Tuesday, July 4, 2017 |
|
|
Wellness Open Living Labs. LLC, Co-Founded by Eisai and Osaka City University Conclude Basic Collaboration Agreement Aimed at Solving Health Problems |
| Eisai Co., Ltd. announced today that Wellness Open Living Labs. LLC, co-founded by Eisai, and Osaka City University have concluded a basic collaboration agreement aimed at solving health science-related problems, such as dementia, and extending healthy life expectancy. more info >> |
|
| Wednesday, June 28, 2017 |
|
|
Eisai Listed for 16th Consecutive Year in FTSE4Good Index Series, an Index for Socially Responsible Investment |
| Eisai Co., Ltd. announced today that it has been included in the FTSE4Good Index Series for the 16th consecutive year since its initial inclusion in 2002. more info >> |
|
| Tuesday, June 27, 2017 |
|
|
Eisai Temporarily Withdraws New Drug Application for Anticancer Agent Halaven in China |
| Eisai Co., Ltd. announced today that, in alignment with Chinese regulations, it has temporarily withdrawn its new drug application for anticancer agent eribulin mesylate (Brand name: Halaven) in China in order to submit additional documentation. more info >> |
|
| Friday, June 23, 2017 |
|
|
Eisai Submits Application for Additional Indication of Anticancer Agent Lenvima for Hepatocellular Carcinoma in Japan |
| Eisai Co., Ltd. announced today that it has submitted an application for an additional indication of its in-house discovered and developed anticancer agent Lenvima (generic name: lenvatinib mesylate) for the treatment of hepatocellular carcinoma (HCC) in Japan, the first in the world. more info >> |
|
|
Cardiovascular Outcomes Trial of Anti-Obesity Agent Lorcaserin to Continue Based on Recommendation of Independent Data Monitoring Committee After Completion of Interim Safety Analysis |
| Eisai Co., Ltd. has announced that it has received a recommendation from an independent Data Monitoring Committee to continue the ongoing Cardiovascular Outcomes Trial of lorcaserin hydrochloride after the completion of a pre-specified interim safety analysis, evaluating the incidence of Major Adverse Cardiovascular Events (MACE), defined as cardiovascular death, myocardial infarction or stroke. more info >> |
|
| Thursday, June 8, 2017 |
|
|
Launch of Pain Treatment Lyrica OD Tablet Formulation in Japan |
| Pfizer Japan Inc. and Eisai Co., Ltd. have announced that Lyrica OD Tablets 25mg, 75mg, 150mg (OD tablet: orally disintegrating tablet), a new formulation following pain treatment Lyrica Capsules (pregabalin). more info >> |
|
| Monday, June 5, 2017 |
|
|
Eisai to Present Results of Phase III Trial of Lenvima (Lenvatinib) as First-Line Treatment for Unresectable Hepatocellular Carcinoma in Oral Session at 53rd ASCO Annual Meeting |
| Eisai Co., Ltd. announced today that the results of a Phase III trial (Study 304) of its in-house discovered and developed anticancer agent lenvatinib mesylate against the comparator sorafenib as first-line treatment for unresectable hepatocellular carcinoma, will be orally presented during the 53rd Annual Meeting of ASCO. more info >> |
|
|
|
|
|
|
|
|
 |
| Latest Press Releases |
|
A New Benchmark for Specialized Technology Stocks in Hong Kong! CiDi's Listing Marks a New Chapter in Commercial Intelligent Driving
Dec 19, 2025 10:30 HKT/SGT
|
|
|
Air T, Inc. Announces Closing of Regional Express Acquisition
Dec 19, 2025 06:10 HKT/SGT
|
|
|
MHI Participates in Demonstration Testing of Vehicle-Infrastructure Integration System for Autonomous Buses in Shimotsuke City
Dec 19, 2025 3:24 JST
|
|
|
NEC and emaratech Collaborate on Biometric Smart Gates Supporting UAE Airport Operations
Dec 19, 2025 3:06 JST
|
|
|
Fujitsu to showcase mobility and physical AI tech at CES 2026
Dec 19, 2025 2:42 JST
|
|
|
Kirin and Fujitsu elucidate a novel gut-brain axis mechanism of citicoline for the first time worldwide through AI-based analysis and experimental validation leveraging drug discovery DX technology
Dec 19, 2025 2:06 JST
|
|
|
TANAKA PRECIOUS METAL GROUP and TANAKA MIRAI Lab. Released Their Fourth Collaborative Musical Work with Sound Wellness Lab (Della): "Precious Metal Orchestra - A Musical Voyage through the Sound of Precious Metals for Christmas" now available for streaming. 
Dec 18, 2025 22:00 JST
|
|
|
Focus Graphite Announces Final Results From 2022 Drill Program at Lac Tetepisca; West Limb Extends Mineralized Strike to 8 KM
Dec 18, 2025 18:09 HKT/SGT
|
|
|
Spritzer MerryLand Returns This Year-End, Bringing Magical Festive Cheer to Taiping
Dec 18, 2025 17:44 HKT/SGT
|
|
|
PropertyGuru Asia Real Estate Summit spotlights PropertyGuru Week 2025 with conversations on 'Trusted Marketplaces and Thriving Communities'
Dec 18, 2025 10:00 JST
|
|
|
TruMerit and NAPNAP Team Up to Develop a Global Micro-credential for Pediatric Nursing Care
Dec 18, 2025 07:00 HKT/SGT
|
|
|
1World Online and Culinary Heritage Announce Strategic Partnership and Joint Launches in Europe
Dec 17, 2025 23:29 HKT/SGT
|
|
|
Anson Resources: Update on Cooperation between Anson and POSCO Holdings for DLE Green River Demonstration Plant
Dec 17, 2025 07:00 HKT/SGT
|
|
|
AWM Wraps Up 2025 with Multiple Surf Venue Grand Openings
Dec 16, 2025 23:05 HKT/SGT
|
|
|
Eastman, AstraZeneca, Kraft Heinz, and P&G Recognized with OMP Supply Chain Awards
Dec 16, 2025 22:00 HKT/SGT
|
|
|
|
|
More Press release >> |
|
|
|
|
|
|
|
